{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:35:46Z","timestamp":1790760946270,"version":"4.1.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T00:00:00Z","timestamp":1518998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/nrneph.2018.8","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T05:14:55Z","timestamp":1519017295000},"page":"246-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Animal models of monoclonal immunoglobulin-related renal diseases"],"prefix":"10.1038","volume":"14","author":[{"given":"Christophe","family":"Sirac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo A.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vecihi","family":"Batuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Javaugue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba A.","family":"Turbat-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Cogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Touchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,19]]},"reference":[{"key":"BFnrneph20188_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ki.2014.408","volume":"87","author":"F Bridoux","year":"2015","unstructured":"Bridoux, F. et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 87, 698\u2013711 (2015).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR2","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","volume":"108","author":"G Merlini","year":"2006","unstructured":"Merlini, G. & Stone, M. J. Dangerous small B-cell clones. Blood 108, 2520\u20132530 (2006).","journal-title":"Blood"},{"key":"BFnrneph20188_CR3","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","volume":"122","author":"J-P Fermand","year":"2013","unstructured":"Fermand, J.-P. et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122, 3583\u20133590 (2013).","journal-title":"Blood"},{"key":"BFnrneph20188_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0192-0561(94)90032-9","volume":"16","author":"JL Preud'homme","year":"1994","unstructured":"Preud'homme, J. L. et al. Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. Int. J. Immunopharmacol. 16, 425\u2013431 (1994).","journal-title":"Int. J. Immunopharmacol."},{"key":"BFnrneph20188_CR5","first-page":"F246","volume":"275","author":"V Batuman","year":"1998","unstructured":"Batuman, V. et al. Myeloma light chains are ligands for cubilin (gp280). Am. J. Physiol. 275, F246\u2013254 (1998).","journal-title":"Am. J. Physiol."},{"key":"BFnrneph20188_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1152\/physiol.00022.2012","volume":"27","author":"EI Christensen","year":"2012","unstructured":"Christensen, E. I., Birn, H., Storm, T., Weyer, K. & Nielsen, R. Endocytic receptors in the renal proximal tubule. Physiology 27, 223\u2013236 (2012).","journal-title":"Physiology"},{"key":"BFnrneph20188_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrneph.2011.168","volume":"8","author":"CA Hutchison","year":"2012","unstructured":"Hutchison, C. A. et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat. Rev. Nephrol. 8, 43\u201351 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph20188_CR8","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph20188_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","volume":"375","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri, A. et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375, 1721\u20131728 (2010).","journal-title":"Lancet"},{"key":"BFnrneph20188_CR10","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"Leung, N. et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120, 4292\u20134295 (2012).","journal-title":"Blood"},{"key":"BFnrneph20188_CR11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1681\/ASN.2012040388","volume":"23","author":"PW Sanders","year":"2012","unstructured":"Sanders, P. W. Mechanisms of light chain injury along the tubular nephron. J. Am. Soc. Nephrol. 23, 1777\u20131781 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph20188_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/0002-9343(75)90601-4","volume":"58","author":"JE Maldonado","year":"1975","unstructured":"Maldonado, J. E. et al. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am. J. Med. 58, 354\u2013364 (1975).","journal-title":"Am. J. Med."},{"key":"BFnrneph20188_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00005792-200005000-00002","volume":"79","author":"T Messiaen","year":"2000","unstructured":"Messiaen, T. et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine 79, 135\u2013154 (2000).","journal-title":"Medicine"},{"key":"BFnrneph20188_CR14","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.5858\/arpa.2013-0493-OA","volume":"138","author":"GA Herrera","year":"2014","unstructured":"Herrera, G. A. Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch. Pathol. Lab. Med. 138, 1365\u20131380 (2014).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"BFnrneph20188_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","volume":"57","author":"MB Pepys","year":"2006","unstructured":"Pepys, M. B. Amyloidosis. Annu. Rev. Med. 57, 223\u2013241 (2006).","journal-title":"Annu. Rev. Med."},{"key":"BFnrneph20188_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1750-1172-7-54","volume":"7","author":"E Desport","year":"2012","unstructured":"Desport, E. et al. AL Amyloidosis. Orphanet J. Rare Dis. 7, 54 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFnrneph20188_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","volume":"75","author":"F Chiti","year":"2006","unstructured":"Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333\u2013366 (2006).","journal-title":"Annu. Rev. Biochem."},{"key":"BFnrneph20188_CR18","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","volume":"104","author":"R Liao","year":"2001","unstructured":"Liao, R. et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104, 1594\u20131597 (2001).","journal-title":"Circulation"},{"key":"BFnrneph20188_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","volume":"94","author":"DA Brenner","year":"2004","unstructured":"Brenner, D. A. et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ. Res. 94, 1008\u20131010 (2004).","journal-title":"Circ. Res."},{"key":"BFnrneph20188_CR20","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","volume":"107","author":"G Palladini","year":"2006","unstructured":"Palladini, G. et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107, 3854\u20133858 (2006).","journal-title":"Blood"},{"key":"BFnrneph20188_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0889-8588(05)70123-4","volume":"13","author":"J Buxbaum","year":"1999","unstructured":"Buxbaum, J. & Gallo, G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol. Oncol. Clin. North Am. 13, 1235\u20131248 (1999).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"BFnrneph20188_CR22","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","volume":"12","author":"J Lin","year":"2001","unstructured":"Lin, J. et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J. Am. Soc. Nephrol. 12, 1482\u20131492 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph20188_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.nephro.2015.12.005","volume":"12","author":"C Cohen","year":"2016","unstructured":"Cohen, C. et al. Randall-type monoclonal immunoglobulin deposition disease: from diagnosis to treatment [French]. Nephrol. Ther. 12, 131\u2013139 (2016).","journal-title":"Nephrol. Ther."},{"key":"BFnrneph20188_CR24","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1056\/NEJM199311043291905","volume":"329","author":"P Aucouturier","year":"1993","unstructured":"Aucouturier, P. et al. Brief report: heavy-chain deposition disease. N. Engl. J. Med. 329, 1389\u20131393 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph20188_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/ki.1994.355","volume":"46","author":"JL Preud'homme","year":"1994","unstructured":"Preud'homme, J. L. et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int. 46, 965\u2013972 (1994).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S0272-6386(99)70432-4","volume":"33","author":"N Kambham","year":"1999","unstructured":"Kambham, N. et al. Heavy chain deposition disease: the disease spectrum. Am. J. Kidney Dis. Off. J. Natl Kidney Found. 33, 954\u2013962 (1999).","journal-title":"Am. J. Kidney Dis. Off. J. Natl Kidney Found."},{"key":"BFnrneph20188_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.kint.2016.09.004","volume":"91","author":"F Bridoux","year":"2017","unstructured":"Bridoux, F. et al. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Kidney Int. 91, 423\u2013434 (2017).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR28","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1172\/JCI46490","volume":"122","author":"W-Z Ying","year":"2012","unstructured":"Ying, W.-Z., Allen, C. E., Curtis, L. M., Aaron, K. J. & Sanders, P. W. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J. Clin. Invest. 122, 1777\u20131785 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph20188_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0167-5699(99)01502-9","volume":"20","author":"FJ Stevens","year":"1999","unstructured":"Stevens, F. J. & Argon, Y. Pathogenic light chains and the B-cell repertoire. Immunol. Today 20, 451\u2013457 (1999).","journal-title":"Immunol. Today"},{"key":"BFnrneph20188_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1006\/jsbi.2000.4248","volume":"130","author":"V Bellotti","year":"2000","unstructured":"Bellotti, V., Mangione, P. & Merlini, G. Review: immunoglobulin light chain amyloidosis \u2014 the archetype of structural and pathogenic variability. J. Struct. Biol. 130, 280\u2013289 (2000).","journal-title":"J. Struct. Biol."},{"key":"BFnrneph20188_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev-biochem-072611-130030","volume":"82","author":"LM Blancas-Mej\u00eda","year":"2013","unstructured":"Blancas-Mej\u00eda, L. M. & Ramirez-Alvarado, M. Systemic amyloidoses. Annu. Rev. Biochem. 82, 745\u2013774 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"BFnrneph20188_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1006\/jmbi.2001.5092","volume":"313","author":"DP Davis","year":"2001","unstructured":"Davis, D. P. et al. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain. J. Mol. Biol. 313, 1021\u20131034 (2001).","journal-title":"J. Mol. Biol."},{"key":"BFnrneph20188_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jmr.681","volume":"17","author":"JS Wall","year":"2004","unstructured":"Wall, J. S. et al. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins. J. Mol. Recognit. 17, 323\u2013331 (2004).","journal-title":"J. Mol. Recognit."},{"key":"BFnrneph20188_CR34","doi-asserted-by":"publisher","first-page":"e5169","DOI":"10.1371\/journal.pone.0005169","volume":"4","author":"TL Poshusta","year":"2009","unstructured":"Poshusta, T. L. et al. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE 4, e5169 (2009).","journal-title":"PLoS ONE"},{"key":"BFnrneph20188_CR35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jmb.2009.11.038","volume":"396","author":"A Hern\u00e1ndez-Santoyo","year":"2010","unstructured":"Hern\u00e1ndez-Santoyo, A. et al. A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis. J. Mol. Biol. 396, 280\u2013292 (2010).","journal-title":"J. Mol. Biol."},{"key":"BFnrneph20188_CR36","doi-asserted-by":"publisher","first-page":"5162","DOI":"10.1021\/bi5007892","volume":"53","author":"Y Kobayashi","year":"2014","unstructured":"Kobayashi, Y. et al. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain. Biochemistry 53, 5162\u20135173 (2014).","journal-title":"Biochemistry"},{"key":"BFnrneph20188_CR37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.V98.3.714","volume":"98","author":"RL Comenzo","year":"2001","unstructured":"Comenzo, R. L., Zhang, Y., Martinez, C., Osman, K. & Herrera, G. A. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 98, 714\u2013720 (2001).","journal-title":"Blood"},{"key":"BFnrneph20188_CR38","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","volume":"100","author":"V Perfetti","year":"2002","unstructured":"Perfetti, V. et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 100, 948\u2013953 (2002).","journal-title":"Blood"},{"key":"BFnrneph20188_CR39","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","volume":"101","author":"RS Abraham","year":"2003","unstructured":"Abraham, R. S. et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101, 3801\u20133808 (2003).","journal-title":"Blood"},{"key":"BFnrneph20188_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","volume":"119","author":"V Perfetti","year":"2012","unstructured":"Perfetti, V. et al. The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 119, 144\u2013150 (2012).","journal-title":"Blood"},{"key":"BFnrneph20188_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1365-2249.1993.tb05932.x","volume":"91","author":"A Rocca","year":"1993","unstructured":"Rocca, A. et al. Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease. Clin. Exp. Immunol. 91, 506\u2013509 (1993).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph20188_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0165-2478(94)90036-1","volume":"42","author":"L Denoroy","year":"1994","unstructured":"Denoroy, L., D\u00e9ret, S. & Aucouturier, P. Overrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol. Lett. 42, 63\u201366 (1994).","journal-title":"Immunol. Lett."},{"key":"BFnrneph20188_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1046\/j.1365-2249.1996.d01-841.x","volume":"106","author":"C Decourt","year":"1996","unstructured":"Decourt, C., Cogn\u00e9, M. & Rocca, A. Structural peculiarities of a truncated V kappa III immunoglobulin light chain in myeloma with light chain deposition disease. Clin. Exp. Immunol. 106, 357\u2013361 (1996).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph20188_CR44","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2141.2006.06488.x","volume":"136","author":"B Kaplan","year":"2007","unstructured":"Kaplan, B., Livneh, A. & Gallo, G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. Br. J. Haematol. 136, 723\u2013728 (2007).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph20188_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/13506129808995289","volume":"5","author":"T Isobe","year":"1998","unstructured":"Isobe, T., Kametani, F. & Shinoda, T. V-Domain deposition of lambda Bence Jones protein in the renal tubular epithelial cells in a patient with the adult Fanconi syndrome with myeloma. Amyloid 5, 117\u2013120 (1998).","journal-title":"Amyloid"},{"key":"BFnrneph20188_CR46","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.ajkd.2004.12.020","volume":"45","author":"F Bridoux","year":"2005","unstructured":"Bridoux, F. et al. Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia. Am. J. Kidney Dis. 45, 749\u2013757 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph20188_CR47","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.4049\/jimmunol.150.8.3561","volume":"150","author":"P Aucouturier","year":"1993","unstructured":"Aucouturier, P. et al. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. J. Immunol. 150, 3561\u20133568 (1993).","journal-title":"J. Immunol."},{"key":"BFnrneph20188_CR48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/ki.1995.269","volume":"48","author":"M Leboulleux","year":"1995","unstructured":"Leboulleux, M. et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int. 48, 72\u201379 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR49","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V94.10.3559.422k10_3559_3566","volume":"94","author":"C Decourt","year":"1999","unstructured":"Decourt, C. et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 94, 3559\u20133566 (1999).","journal-title":"Blood"},{"key":"BFnrneph20188_CR50","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1681\/ASN.2015050581","volume":"27","author":"A Luciani","year":"2016","unstructured":"Luciani, A. et al. Impaired lysosomal function underlies monoclonal light chain-associated renal Fanconi syndrome. J. Am. Soc. Nephrol. 27, 2049\u20132061 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph20188_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ki.2012.414","volume":"83","author":"SH Nasr","year":"2013","unstructured":"Nasr, S. H. et al. The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 83, 463\u2013470 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20436.x","volume":"229","author":"AA Khamlichi","year":"1995","unstructured":"Khamlichi, A. A., Aucouturier, P., Preud'homme, J. L. & Cogn\u00e9, M. Structure of abnormal heavy chains in human heavy-chain-deposition disease. Eur. J. Biochem. 229, 54\u201360 (1995).","journal-title":"Eur. J. Biochem."},{"key":"BFnrneph20188_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1083\/jcb.104.3.761","volume":"104","author":"L Hendershot","year":"1987","unstructured":"Hendershot, L., Bole, D., K\u00f6hler, G. & Kearney, J. F. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J. Cell Biol. 104, 761\u2013767 (1987).","journal-title":"J. Cell Biol."},{"key":"BFnrneph20188_CR54","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood.V79.9.2181.2181","volume":"79","author":"M Cogn\u00e9","year":"1992","unstructured":"Cogn\u00e9, M., Silvain, C., Khamlichi, A. A. & Preud'homme, J. L. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood 79, 2181\u20132195 (1992).","journal-title":"Blood"},{"key":"BFnrneph20188_CR55","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/ki.1987.286","volume":"32","author":"PW Sanders","year":"1987","unstructured":"Sanders, P. W., Herrera, G. A. & Galla, J. H. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int. 32, 851\u2013861 (1987).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR56","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1172\/JCI113830","volume":"82","author":"PW Sanders","year":"1988","unstructured":"Sanders, P. W., Herrera, G. A., Chen, A., Booker, B. B. & Galla, J. H. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J. Clin. Invest. 82, 2086\u20132096 (1988).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph20188_CR57","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJM199106273242603","volume":"324","author":"A Solomon","year":"1991","unstructured":"Solomon, A., Weiss, D. T. & Kattine, A. A. Nephrotoxic potential of Bence Jones proteins. N. Engl. J. Med. 324, 1845\u20131851 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph20188_CR58","first-page":"629","volume":"140","author":"A Solomon","year":"1992","unstructured":"Solomon, A., Weiss, D. T. & Pepys, M. B. Induction in mice of human light-chain-associated amyloidosis. Am. J. Pathol. 140, 629\u2013637 (1992).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph20188_CR59","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1159\/000317129","volume":"116","author":"A-M Khan","year":"2010","unstructured":"Khan, A.-M. et al. Myeloma light chain-induced renal injury in mice. Nephron Exp. Nephrol. 116, e32\u2013e41 (2010).","journal-title":"Nephron Exp. Nephrol."},{"key":"BFnrneph20188_CR60","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood.V86.10.3655.bloodjournal86103655","volume":"86","author":"AA Khamlichi","year":"1995","unstructured":"Khamlichi, A. A. et al. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 86, 3655\u20133659 (1995).","journal-title":"Blood"},{"key":"BFnrneph20188_CR61","doi-asserted-by":"publisher","first-page":"e76022","DOI":"10.1371\/journal.pone.0076022","volume":"8","author":"P Rognoni","year":"2013","unstructured":"Rognoni, P. et al. A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. PLoS ONE 8, e76022 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneph20188_CR62","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ki.2014.122","volume":"86","author":"J Teng","year":"2014","unstructured":"Teng, J., Turbat-Herrera, E. A. & Herrera, G. A. An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes. Kidney Int. 86, 738\u2013746 (2014).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR63","first-page":"579","volume":"34","author":"MN Koss","year":"1976","unstructured":"Koss, M. N., Pirani, C. L. & Osserman, E. F. Experimental Bence Jones cast nephropathy. Lab. Invest. 34, 579\u2013591 (1976).","journal-title":"Lab. Invest."},{"key":"BFnrneph20188_CR64","doi-asserted-by":"publisher","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","volume":"305","author":"S Mishra","year":"2013","unstructured":"Mishra, S. et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am. J. Physiol. Heart Circ. Physiol. 305, H95\u2013H103 (2013).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrneph20188_CR65","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","volume":"123","author":"L Diomede","year":"2014","unstructured":"Diomede, L. et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 123, 3543\u20133552 (2014).","journal-title":"Blood"},{"key":"BFnrneph20188_CR66","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/blood-2013-10-535187","volume":"123","author":"P Zhou","year":"2014","unstructured":"Zhou, P., Ma, X., Iyer, L., Chaulagain, C. & Comenzo, R. L. One siRNA pool targeting the \u03bb constant region stops \u03bb light-chain production and causes terminal endoplasmic reticulum stress. Blood 123, 3440\u20133451 (2014).","journal-title":"Blood"},{"key":"BFnrneph20188_CR67","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/gt.2011.69","volume":"18","author":"BM Hovey","year":"2011","unstructured":"Hovey, B. M. et al. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther. 18, 1150\u20131156 (2011).","journal-title":"Gene Ther."},{"key":"BFnrneph20188_CR68","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0378-1119(98)00475-2","volume":"222","author":"C Chauveau","year":"1998","unstructured":"Chauveau, C., Decourt, C. & Cogn\u00e9, M. Insertion of the IgH locus 3\u2032 regulatory palindrome in expression vectors warrants sure and efficient expression in stable B cell transfectants. Gene 222, 279\u2013285 (1998).","journal-title":"Gene"},{"key":"BFnrneph20188_CR69","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2017.1289914","volume":"24","author":"M Nuvolone","year":"2017","unstructured":"Nuvolone, M. et al. Regulated expression of amyloidogenic immunoglobulin light chains in mice. Amyloid 24, 52\u201353 (2017).","journal-title":"Amyloid"},{"key":"BFnrneph20188_CR70","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","volume":"118","author":"JE Ward","year":"2011","unstructured":"Ward, J. E. et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood 118, 6610\u20136617 (2011).","journal-title":"Blood"},{"key":"BFnrneph20188_CR71","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2005-11-4419","volume":"108","author":"C Sirac","year":"2006","unstructured":"Sirac, C. et al. Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood 108, 536\u2013543 (2006).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"BFnrneph20188_CR72","first-page":"40","volume":"18","author":"C Sirac","year":"2011","unstructured":"Sirac, C. et al. Strategies to model AL amyloidosis in mice. Amyloid 18 (Suppl. 1), 40\u201342 (2011).","journal-title":"Amyloid"},{"key":"BFnrneph20188_CR73","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1182\/blood-2015-03-630277","volume":"126","author":"A Bonaud","year":"2015","unstructured":"Bonaud, A. et al. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. Blood 126, 757\u2013765 (2015).","journal-title":"Blood"},{"key":"BFnrneph20188_CR74","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ni1036","volume":"5","author":"S Casola","year":"2004","unstructured":"Casola, S. et al. B cell receptor signal strength determines B cell fate. Nat. Immunol. 5, 317\u2013327 (2004).","journal-title":"Nat. Immunol."},{"key":"BFnrneph20188_CR75","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/eji.201242912","volume":"43","author":"F Lechouane","year":"2013","unstructured":"Lechouane, F. et al. B-Cell receptor signal strength influences terminal differentiation. Eur. J. Immunol. 43, 619\u2013628 (2013).","journal-title":"Eur. J. Immunol."},{"key":"BFnrneph20188_CR76","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","volume":"157","author":"R Hrncic","year":"2000","unstructured":"Hrncic, R. et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am. J. Pathol. 157, 1239\u20131246 (2000).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph20188_CR77","first-page":"3831S","volume":"9","author":"A Solomon","year":"2003","unstructured":"Solomon, A., Weiss, D. T. & Wall, J. S. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin. Cancer Res. 9, 3831S\u20133838S (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrneph20188_CR78","doi-asserted-by":"publisher","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","volume":"7","author":"JS Wall","year":"2012","unstructured":"Wall, J. S. et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE 7, e52686 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrneph20188_CR79","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","volume":"34","author":"MA Gertz","year":"2016","unstructured":"Gertz, M. A. et al. First-in-Human Phase I\/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J. Clin. Oncol. 34, 1097\u20131103 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph20188_CR80","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/jps.2600620549","volume":"62","author":"CH Nightingale","year":"1973","unstructured":"Nightingale, C. H. & Mouravieff, M. Reliable and simple method of intravenous injection into the laboratory rat. J. Pharm. Sci. 62, 860\u2013861 (1973).","journal-title":"J. Pharm. Sci."},{"key":"BFnrneph20188_CR81","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/labinvest.3700069","volume":"84","author":"J Teng","year":"2004","unstructured":"Teng, J. et al. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab. Invest. 84, 440\u2013451 (2004).","journal-title":"Lab. Invest."},{"key":"BFnrneph20188_CR82","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3109\/01913123.2013.861568","volume":"38","author":"J Teng","year":"2014","unstructured":"Teng, J., Turbat-Herrera, E. A. & Herrera, G. A. Extrusion of amyloid fibrils to the extracellular space in experimental mesangial AL-amyloidosis: transmission and scanning electron microscopy studies and correlation with renal biopsy observations. Ultrastruct. Pathol. 38, 104\u2013115 (2014).","journal-title":"Ultrastruct. Pathol."},{"key":"BFnrneph20188_CR83","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/art.10335","volume":"46","author":"B Kluve-Beckerman","year":"2002","unstructured":"Kluve-Beckerman, B., Manaloor, J. J. & Liepnieks, J. J. A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum. 46, 1905\u20131913 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph20188_CR84","doi-asserted-by":"publisher","first-page":"e79104","DOI":"10.1371\/journal.pone.0079104","volume":"8","author":"K Lundmark","year":"2013","unstructured":"Lundmark, K., Vahdat Shariatpanahi, A. & Westermark, G. T. Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. PLoS ONE 8, e79104 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneph20188_CR85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/13506129.2013.876400","volume":"21","author":"SJ Kennel","year":"2014","unstructured":"Kennel, S. J. et al. Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice. Amyloid 21, 45\u201353 (2014).","journal-title":"Amyloid"},{"key":"BFnrneph20188_CR86","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood-2008-03-143040","volume":"112","author":"BK Arendt","year":"2008","unstructured":"Arendt, B. K. et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 112, 1931\u20131941 (2008).","journal-title":"Blood"},{"key":"BFnrneph20188_CR87","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/j.febslet.2009.07.031","volume":"583","author":"JN Buxbaum","year":"2009","unstructured":"Buxbaum, J. N. Animal models of human amyloidoses: are transgenic mice worth the time and trouble? FEBS Lett. 583, 2663\u20132673 (2009).","journal-title":"FEBS Lett."},{"key":"BFnrneph20188_CR88","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1038\/bcj.2017.26","volume":"7","author":"AD Wechalekar","year":"2017","unstructured":"Wechalekar, A. D. & Whelan, C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 7, e546 (2017).","journal-title":"Blood Cancer J."},{"key":"BFnrneph20188_CR89","first-page":"327","volume":"70","author":"H Rokita","year":"1989","unstructured":"Rokita, H., Shirahama, T., Cohen, A. S. & Sipe, J. D. Serum amyloid A gene expression and AA amyloid formation in A\/J and SJL\/J mice. Br. J. Exp. Pathol. 70, 327\u2013335 (1989).","journal-title":"Br. J. Exp. Pathol."},{"key":"BFnrneph20188_CR90","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0167-4943(94)90039-6","volume":"19","author":"T Takeda","year":"1994","unstructured":"Takeda, T. et al. A novel murine model of aging, Senescence-Accelerated Mouse (SAM). Arch. Gerontol. Geriatr. 19, 185\u2013192 (1994).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"BFnrneph20188_CR91","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/labinvest.3700559","volume":"87","author":"F Ge","year":"2007","unstructured":"Ge, F. et al. Amyloidosis in transgenic mice expressing murine amyloidogenic apolipoprotein A-II (Apoa2c). Lab. Invest. 87, 633\u2013643 (2007).","journal-title":"Lab. Invest."},{"key":"BFnrneph20188_CR92","first-page":"1497","volume":"150","author":"K Kohno","year":"1997","unstructured":"Kohno, K. et al. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am. J. Pathol. 150, 1497\u20131508 (1997).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph20188_CR93","doi-asserted-by":"publisher","first-page":"16115","DOI":"10.1073\/pnas.1306621110","volume":"110","author":"JP Simons","year":"2013","unstructured":"Simons, J. P. et al. Pathogenetic mechanisms of amyloid A amyloidosis. Proc. Natl Acad. Sci. USA 110, 16115\u201316120 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph20188_CR94","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","volume":"13","author":"M Chesi","year":"2008","unstructured":"Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167\u2013180 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrneph20188_CR95","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","volume":"11","author":"DR Carrasco","year":"2007","unstructured":"Carrasco, D. R. et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11, 349\u2013360 (2007).","journal-title":"Cancer Cell"},{"key":"BFnrneph20188_CR96","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1084\/jem.20150983","volume":"213","author":"M-A Hamouda","year":"2016","unstructured":"Hamouda, M.-A. et al. BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. J. Exp. Med. 213, 1705\u20131722 (2016).","journal-title":"J. Exp. Med."},{"key":"BFnrneph20188_CR97","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi, J. et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc. Natl Acad. Sci. USA 107, 4188\u20134193 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph20188_CR98","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.15252\/emmm.201404190","volume":"6","author":"J Guan","year":"2014","unstructured":"Guan, J. et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol. Med. 6, 1493\u20131507 (2014).","journal-title":"EMBO Mol. Med."},{"key":"BFnrneph20188_CR99","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/13506129.2012.733741","volume":"19","author":"JT Shin","year":"2012","unstructured":"Shin, J. T. et al. Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid 19, 191\u2013196 (2012).","journal-title":"Amyloid"},{"key":"BFnrneph20188_CR100","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/ars.2016.6848","volume":"27","author":"L Diomede","year":"2017","unstructured":"Diomede, L. et al. Cardiac light chain amyloidosis: the role of metal ions in oxidative stress and mitochondrial damage. Antioxid. Redox Signal. 27, 567\u2013582 (2017).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrneph20188_CR101","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000443282","volume":"132","author":"GA Herrera","year":"2016","unstructured":"Herrera, G. A., Turbat-Herrera, E. A. & Teng, J. Animal models of light chain deposition disease provide a better understanding of nodular glomerulosclerosis. Nephron 132, 119\u2013136 (2016).","journal-title":"Nephron"},{"key":"BFnrneph20188_CR102","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000314778","volume":"169","author":"P Ronco","year":"2011","unstructured":"Ronco, P., Plaisier, E. & Aucouturier, P. Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common renal diseases. Contrib. Nephrol. 169, 221\u2013231 (2011).","journal-title":"Contrib. Nephrol."},{"key":"BFnrneph20188_CR103","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1046\/j.1523-1755.1998.00219.x","volume":"54","author":"F Zheng","year":"1998","unstructured":"Zheng, F., Striker, G. E., Esposito, C., Lupia, E. & Striker, L. J. Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int. 54, 1999\u20132007 (1998).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR104","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1046\/j.1523-1755.2003.00058.x","volume":"64","author":"L-J Ma","year":"2003","unstructured":"Ma, L.-J. & Fogo, A. B. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int. 64, 350\u2013355 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR105","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","volume":"129","author":"L Oliva","year":"2017","unstructured":"Oliva, L. et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood 129, 2132\u20132142 (2017).","journal-title":"Blood"},{"key":"BFnrneph20188_CR106","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister, S. et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783\u20131792 (2007).","journal-title":"Cancer Res."},{"key":"BFnrneph20188_CR107","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2215\/CJN.08640811","volume":"7","author":"SH Nasr","year":"2012","unstructured":"Nasr, S. H. et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin. J. Am. Soc. Nephrol. 7, 231\u2013239 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph20188_CR108","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ki.2015.201","volume":"88","author":"C Cohen","year":"2015","unstructured":"Cohen, C. et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 88, 1135\u20131143 (2015).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR109","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/leu.2014.218","volume":"28","author":"CP Venner","year":"2014","unstructured":"Venner, C. P. et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 28, 2304\u20132310 (2014).","journal-title":"Leukemia"},{"key":"BFnrneph20188_CR110","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/leu.2014.227","volume":"28","author":"G Palladini","year":"2014","unstructured":"Palladini, G. et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia 28, 2311\u20132316 (2014).","journal-title":"Leukemia"},{"key":"BFnrneph20188_CR111","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","volume":"99","author":"A Jaccard","year":"2014","unstructured":"Jaccard, A. et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-na\u00efve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 99, 1479\u20131485 (2014).","journal-title":"Haematologica"},{"key":"BFnrneph20188_CR112","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis, E. et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J. Clin. Oncol. 28, 1031\u20131037 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph20188_CR113","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/ki.1986.237","volume":"30","author":"V Batuman","year":"1986","unstructured":"Batuman, V., Sastrasinh, M. & Sastrasinh, S. Light chain effects on alanine and glucose uptake by renal brush border membranes. Kidney Int. 30, 662\u2013665 (1986).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR114","first-page":"294","volume":"17","author":"V Batuman","year":"1994","unstructured":"Batuman, V., Guan, S., O'Donovan, R. & Puschett, J. B. Effect of myeloma light chains on phosphate and glucose transport in renal proximal tubule cells. Ren. Physiol. Biochem. 17, 294\u2013300 (1994).","journal-title":"Ren. Physiol. Biochem."},{"key":"BFnrneph20188_CR115","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1053\/ajkd.2000.17620","volume":"36","author":"A Pote","year":"2000","unstructured":"Pote, A., Zwizinski, C., Simon, E. E., Meleg-Smith, S. & Batuman, V. Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am. J. Kidney Dis. 36, 735\u2013744 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph20188_CR116","doi-asserted-by":"publisher","first-page":"F1245","DOI":"10.1152\/ajprenal.00350.2002","volume":"284","author":"S Sengul","year":"2003","unstructured":"Sengul, S., Zwizinski, C. & Batuman, V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am. J. Physiol. Renal Physiol. 284, F1245\u2013F1254 (2003).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph20188_CR117","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1681\/ASN.2006111299","volume":"18","author":"P-X Wang","year":"2007","unstructured":"Wang, P.-X. & Sanders, P. W. Immunoglobulin light chains generate hydrogen peroxide. J. Am. Soc. Nephrol. 18, 1239\u20131245 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph20188_CR118","doi-asserted-by":"publisher","first-page":"F82","DOI":"10.1152\/ajprenal.00091.2008","volume":"295","author":"M Li","year":"2008","unstructured":"Li, M., Balamuthusamy, S., Simon, E. E. & Batuman, V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am. J. Physiol. Renal Physiol. 295, F82\u2013F90 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph20188_CR119","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1182\/blood-2010-08-302505","volume":"117","author":"W-Z Ying","year":"2011","unstructured":"Ying, W.-Z., Wang, P.-X., Aaron, K. J., Basnayake, K. & Sanders, P. W. Immunoglobulin light chains activate nuclear factor-\u03baB in renal epithelial cells through a Src-dependent mechanism. Blood 117, 1301\u20131307 (2011).","journal-title":"Blood"},{"key":"BFnrneph20188_CR120","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000313962","volume":"169","author":"C Sirac","year":"2011","unstructured":"Sirac, C. et al. Toward understanding renal Fanconi syndrome: step by step advances through experimental models. Contrib. Nephrol. 169, 247\u2013261 (2011).","journal-title":"Contrib. Nephrol."},{"key":"BFnrneph20188_CR121","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1093\/hmg\/ddt617","volume":"23","author":"C Raggi","year":"2014","unstructured":"Raggi, C. et al. Dedifferentiation and aberrations of the endolysosomal compartment characterize the early stage of nephropathic cystinosis. Hum. Mol. Genet. 23, 2266\u20132278 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneph20188_CR122","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/01913123.2015.1013653","volume":"39","author":"J Aufman","year":"2015","unstructured":"Aufman, J. & Herrera, G. A. Circulating monoclonal light chains and acute kidney injury: the role of the renal biopsy with emphasis on ultrastructural evaluation in assessing and understanding renal injury. Ultrastruct. Pathol. 39, 159\u2013168 (2015).","journal-title":"Ultrastruct. Pathol."},{"key":"BFnrneph20188_CR123","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ki.1981.122","volume":"20","author":"JH Weiss","year":"1981","unstructured":"Weiss, J. H. et al. Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney Int. 20, 198\u2013210 (1981).","journal-title":"Kidney Int."},{"key":"BFnrneph20188_CR124","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1172\/JCI115629","volume":"89","author":"PW Sanders","year":"1992","unstructured":"Sanders, P. W. & Booker, B. B. Pathobiology of cast nephropathy from human Bence Jones proteins. J. Clin. Invest. 89, 630\u2013639 (1992).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph20188_CR125","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1172\/JCI116920","volume":"92","author":"ZQ Huang","year":"1993","unstructured":"Huang, Z. Q., Kirk, K. A., Connelly, K. G. & Sanders, P. W. Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J. Clin. Invest. 92, 2975\u20132983 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph20188_CR126","first-page":"810","volume":"73","author":"ZQ Huang","year":"1995","unstructured":"Huang, Z. Q. & Sanders, P. W. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab. Invest. 73, 810\u2013817 (1995).","journal-title":"Lab. Invest."},{"key":"BFnrneph20188_CR127","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1172\/JCI119218","volume":"99","author":"ZQ Huang","year":"1997","unstructured":"Huang, Z. Q. & Sanders, P. W. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J. Clin. Invest. 99, 732\u2013736 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph20188_CR128","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0002-9440(10)64142-9","volume":"158","author":"WZ Ying","year":"2001","unstructured":"Ying, W. Z. & Sanders, P. W. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am. J. Pathol. 158, 1859\u20131866 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph20188_CR129","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1681\/ASN.2006020139","volume":"17","author":"SM Korbet","year":"2006","unstructured":"Korbet, S. M. & Schwartz, M. M. Multiple myeloma. J. Am. Soc. Nephrol. 17, 2533\u20132545 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph20188_CR130","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2006-03-008953","volume":"108","author":"M Drayson","year":"2006","unstructured":"Drayson, M. et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 108, 2013\u20132019 (2006).","journal-title":"Blood"},{"key":"BFnrneph20188_CR131","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards, D. B. et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N. Engl. J. Med. 373, 1106\u20131114 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph20188_CR132","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1021\/acs.biochem.6b01043","volume":"56","author":"LM Blancas-Mej\u00eda","year":"2017","unstructured":"Blancas-Mej\u00eda, L. M., Misra, P. & Ramirez-Alvarado, M. Differences in protein concentration dependence for nucleation and elongation in light chain amyloid formation. Biochemistry 56, 757\u2013766 (2017).","journal-title":"Biochemistry"},{"key":"BFnrneph20188_CR133","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/ndt\/gft071","volume":"28","author":"GJ Becker","year":"2013","unstructured":"Becker, G. J. & Hewitson, T. D. Animal models of chronic kidney disease: useful but not perfect. Nephrol. Dial. Transplant. 28, 2432\u20132438 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph20188_CR134","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1084\/jem.20131511","volume":"213","author":"N Srour","year":"2016","unstructured":"Srour, N. et al. A plasma cell differentiation quality control ablates B cell clones with biallelic Ig rearrangements and truncated Ig production. J. Exp. Med. 213, 109\u2013122 (2016).","journal-title":"J. Exp. Med."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2018.8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2018.8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneph.2018.8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2018.8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T03:01:58Z","timestamp":1693537318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2018.8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,19]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFnrneph20188"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2018.8","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,19]]},"assertion":[{"value":"19 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}